{"id":25367,"date":"2025-03-03T16:25:40","date_gmt":"2025-03-03T15:25:40","guid":{"rendered":"https:\/\/www.izb-online.de\/?p=25367"},"modified":"2025-03-05T11:15:20","modified_gmt":"2025-03-05T10:15:20","slug":"invitris-selected-for-eic-accelerator-revolutionizing-personalized-medicine","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/invitris-selected-for-eic-accelerator-revolutionizing-personalized-medicine\/","title":{"rendered":"Invitris Secures Prestigious EIC Accelerator Funding to Advance Personalized Medicine"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

Invitris Secures Prestigious EIC Accelerator Funding to Advance Personalized Medicine<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]EIC Accelerator grant provides multi-million \u20ac in nondilutive funding and equity investment[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]March, 2025[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”25370″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 Invitris[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription” el_id=”corona-ausblenden”]Dr. Kathrin Ladetzki-Baehs, Gr\u00fcnderin und Gesch\u00e4ftsf\u00fchrerin von adivo GmbH; Dr. Markus Waldhuber, Gr\u00fcnder und Gesch\u00e4ftsf\u00fchrer adivo GmbH (v.ln.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text css=””]<\/p>\n

\u201cThese funds will enable Invitris to scale our Phactory platform to develop personalized protein-based treatments and reach the next maturity stage of the company.\u201d<\/h6>\n

Dr. Patrick Grossmann, CEO & co-founder of Invitris<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]Invitris, an IZB-based biotech startup, has announced that it has been selected for the European Innovation Council (EIC) Accelerator. This selection places Invitris among the 71 pioneering companies chosen from a highly competitive pool of over 1,200 applicants in the program\u2019s most rigorous funding round to date.<\/p>\n

The EIC Accelerator is Europe\u2019s largest and most prestigious funding initiative for high-risk, high-impact startups in deep tech and life sciences. Through a combination of non-dilutive grants and equity investment, it provides selected companies with the resources needed to scale their innovations and bring breakthrough technologies to market.<\/p>\n

What This Means for Invitris
\n<\/strong>This multi-million-euro funding will enable Invitris to:<\/p>\n